Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bladder cancer
Biotech
CG’s newest late-stage bladder cancer results broaden potential
CG Oncology’s phase 3 results show that its immunotherapy can have a wider impact on certain patients with non-muscle invasive bladder cancer.
Michael Gibney
Nov 16, 2026 2:05pm
Virtuoso abs FDA OK for robotic bladder lesions system
Nov 13, 2026 3:54am
Tyra rolls toward pivotal cancer study even as stock deflates
Sep 9, 2026 9:30am
ASCO: Lilly debuts ‘strong’ data for potential Padcev challenger
May 29, 2026 8:00am
EnGene cancer sales forecast cut after new data widen gap to J&J
May 8, 2026 9:08am
Protara sees 66% bladder cancer response rate at 6 months
Feb 24, 2026 6:50am